David Fenyö has become a staff scientist at Amersham Biosciences, joining the company in January. Prior to that, he was director of proteomics at Ann Arbor, Mich.-based Genomic Solutions. He joined Genomic Solutions in 2002 after it acquired the technology of ProteoMetrics of New York, which Fenyö co-founded and where he served as president. He holds a PhD in physics from Uppsala University in Sweden.
Michael Washburn has been appointed as director of proteomics at the Kansas City, Mo.-based Stowers Institute for Medical Research. He will join the institute later this year from the Torrey Mesa Research Institute in San Diego, where he is a senior staff scientist in proteomics. He holds a BA in chemistry from Grinnell College and a PhD in biochemistry and environmental toxicology from Michigan State University and did a postdoc with John Yates at the University of Washington.
Tim Sutton has become CFO of Huntingdon, UK-based NextGen Sciences as well as a member of the company’s board of directors. Previously, he worked with companies that include T-Mobile UK, Adaptive Broadband, and Quante.
David Campbell has been promoted to the newly-created position of senior vice president for chemical sciences at ActivX Biosciences. Prior to joining the La Jolla, Calif.-based company in 2001, he was director of discovery chemistry at Bayer. Before that, he held various positions at Affymax Research Institute. Campbell holds a BS in chemistry from Harvey Mudd College and a PhD in organic chemistry from Cornell University.
RJ Twilegar has become CEO of Madison, Wis.-based GWC Instruments. He was a professor of entrepreneurship at the Universidad San Francisco de Quito in Ecuador. Twilegar holds a JD from George Washington University School.
GWC also appointed Tim Burland as vice president for technology development. Most recently he was general manager of DNASTAR. He holds a PhD in genetics from the University of Leicester in the UK.